PT-141 / Bremelanotide: From the Tan-Sex Sunscreen to FDA Approval and Back

The Tanning Program That Wasn't

Palatin Technologies, a small New Jersey biotech, started developing PT-141 in the 1990s with a specific commercial goal: a tanning drug that would work without UV exposure. The molecular biology of pigmentation centers on alpha-melanocyte-stimulating hormone, α-MSH, a 13-amino-acid pituitary peptide that acts on melanocortin-1 receptors on melanocytes to drive melanin production. A stable, potent α-MSH analog could, in principle, produce tanning on demand. The market opportunity was clear — a sun-free tan, valuable both cosmetically and for indoor populations seeking protection without UV exposure.

The compound they developed was a heptapeptide. The structure is a cyclic peptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, a substantially modified version of the α-MSH core sequence designed to resist proteolytic degradation and to favor MC4R activity over the broader receptor profile of native α-MSH.

The tanning effect was real but secondary. During Phase I dose-escalation trials, the unusual signal that drove the program's redirection wasn't pigmentation. It was sexual arousal. Several participants reported spontaneous erections in the higher dose groups, with effects that didn't track to anything in the original trial design. The signal was strong enough and reproducible enough that Palatin pivoted the development program to investigate sexual function as the primary target.

Phase II and the Sexual Function Pivot

The Phase II program in male erectile dysfunction looked promising initially. PT-141 produced erectile responses in patients who hadn't responded adequately to PDE5 inhibitors (sildenafil, tadalafil), suggesting it accessed a different downstream mechanism. The fact that it acted centrally on melanocortin receptors rather than peripherally on smooth muscle cGMP signaling made it a potential alternative for the patient population that didn't get adequate response from the established oral drugs.

The Phase III development for ED ran into trouble with adverse events. The non-selective receptor activity produced consistent dose-dependent blood pressure increases that were difficult to manage in the cardiovascular-comorbid population that makes up much of the ED patient base. The program was deprioritized in favor of female sexual dysfunction indications, where the patient population had different cardiovascular risk profiles and the regulatory pathway looked more achievable.

HSDD and the Vyleesi Approval

Hypoactive sexual desire disorder is a clinical diagnosis defined by persistently low sexual desire causing significant distress, with desire deficiency not attributable to other causes. It's controversial as a clinical entity, with substantial debate about diagnostic boundaries and treatment thresholds. But it's also a real population of patients, and the FDA had approved one drug for premenopausal HSDD before — flibanserin (Addyi), in 2015 — establishing a regulatory pathway.

Palatin partnered with AMAG Pharmaceuticals for the Phase III HSDD program. The trial design used validated measures of sexual desire (the Female Sexual Function Index desire domain) and distress (the Female Sexual Distress Scale) as co-primary endpoints. Two Phase III trials, RECONNECT 1 and RECONNECT 2, enrolled approximately 1,200 premenopausal women with HSDD. Both trials met their primary endpoints with statistically significant improvements over placebo.

The FDA approval came in June 2019 under the brand name Vyleesi. Indication: hypoactive sexual desire disorder in premenopausal women. Administration: subcutaneous self-injection 45 minutes before anticipated sexual activity, no more than once per 24 hours and no more than 8 doses per month. The label included warnings about transient blood pressure increases, nausea, and skin pigmentation changes.

Commercial Reality and the AMAG Return

Vyleesi launched in 2019 to modest reception. The injectable route of administration was a substantial commercial barrier — most patients with mild-to-moderate sexual function complaints prefer oral therapy. The 40% nausea rate in pivotal trials translated to real-world prescribing reluctance. The flibanserin precedent had already established that the FSD market is difficult to capture commercially even with FDA approval.

AMAG returned the Vyleesi rights to Palatin in 2020. The drug remains on the market, but at much lower commercial volume than the original development program had projected. Palatin continues to develop melanocortin agonists for other indications — dry eye disease, ulcerative colitis, ocular conditions — using the broader receptor pharmacology platform that PT-141 helped establish.

The Research Use Profile

For laboratory research, PT-141 is interesting for two reasons. First, it's a relatively well-characterized non-selective melanocortin receptor agonist, useful as a pharmacological tool for studying MC1, MC3, MC4, and MC5 receptor biology. Second, the FDA approval and the substantial Phase III trial dataset provide pharmacokinetic and tolerability anchors that most research peptides lack.

The MC4R-mediated effects on appetite and energy expenditure have been studied extensively in animal models, with PT-141 producing reductions in food intake and modest weight effects in some experimental conditions. The MC3R activity has been less thoroughly characterized but appears to influence inflammatory responses and energy homeostasis through somewhat different mechanisms. Cell culture work using PT-141 as a non-selective MCR agonist is straightforward, with the receptor selectivity profile well-documented across the published literature.

For research applications targeting MC4R specifically, more selective compounds (setmelanotide, for example, which is FDA-approved for monogenic obesity syndromes) are sometimes preferred. PT-141's strength as a research tool is its broader receptor coverage and its substantial body of human pharmacokinetic data, both of which make it a reasonable starting point for translational pharmacology questions.

Sources: Palatin Technologies SEC filings, 2002-2020; Edinger et al., Journal of Sexual Medicine, 2018; RECONNECT 1 and RECONNECT 2 trial publications, Obstetrics & Gynecology, 2019; Vyleesi prescribing information, FDA approved label, 2019; Diamond et al., Journal of Sexual Medicine, 2006 (early Phase II); King et al., Pharmacology Biochemistry Behavior, 2007 (mechanism).